Chiron’s Net Soars as Sales Jump
From Bloomberg News
Chiron Corp. said fourth-quarter profit jumped 50% on demand for drugs and blood tests.
Net income climbed to $67.1 million, or 35 cents a share, from $44.8 million, or 23 cents, in the same quarter of 2001. Revenue climbed 12% to $356.3 million as sales increased in all product lines, including medicines for cancer, multiple sclerosis and cystic fibrosis.
Shares of Chiron fell 26 cents to $37.97 on Nasdaq after the earnings were announced.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
